Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02164916
Title S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Southwest Oncology Group

colon adenocarcinoma

rectum adenocarcinoma


Cetuximab + Irinotecan

Cetuximab + Irinotecan + Vemurafenib

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST